Ifosfamide is an alkylating drug indicated in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. It is available as powder for injection and injection for intravenous use. MedsAcross supplies Ifosfamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
IFEX is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. IFEX is an alkylating drug indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer.
Source: US FDA prescribing information
Ifosfamide is a prodrug that requires metabolic activation by hepatic cytochrome P450 isoenzymes to exert its cytotoxic activity. Activation occurs by hydroxylation at the ring carbon atom forming the unstable intermediate 4-hydroxyifosfamide and its ring-opened aldo tautomer, which decomposes to yield the cytotoxic and urotoxic compound acrolein and an alkylating isophosphoramide mustard. The exact mechanism of action of ifosfamide has not been determined, but its cytotoxic action is primarily through DNA crosslinks caused by alkylation by the isophosphoramide mustard at guanine N-7 positions. The formation of inter- and intra-strand cross-links in the DNA results in cell death.
Source: US FDA prescribing information
• Administer IFEX with extensive hydration consisting of at least 2 liters of oral or intravenous fluid per day to reduce the incidence or severity of bladder toxicity. • Administer mesna with IFEX to reduce the incidence or severity of hemorrhagic cystitis. • Administer IFEX as a slow intravenous infusion (at least 30 minutes) at a dose of 1.2 grams per m 2 per day for 5 consecutive days. Repeat every 3 weeks or after recovery from hematologic toxicity. • Individualize the dose and dosing schedule of IFEX based on patient risk factors and adverse reactions. • See Full Prescribing Information for instructions on preparation and administration.
Source: US FDA prescribing information
IFEX is contraindicated in patients with: • Known hypersensitivity to administration of ifosfamide. • Urinary outflow obstruction. • Known hypersensitivity to administration of ifosfamide. • Urinary outflow obstruction.
Source: US FDA prescribing information
Boxed warning (myelosuppression, encephalopathy, nephrotoxicity and urotoxicity •): Myelosuppression can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle. • Encephalopathy can be severe and may result in death. Monitor for CNS toxicity and discontinue treatment for encephalopathy. • Nephrotoxicity can be severe and result in renal failure. • Myelosuppression: Monitor blood counts prior to treatment, during treatment, and as clinically indicated. • Encephalopathy: Monitor for signs and symptoms of CNS toxicity during and after IFEX treatment. Dose interruption or permanent discontinuation may be required based on individual safety and tolerability. • Nephrotoxicity and Urotoxicity: Monitor signs and symptoms. Monitor serum and urine chemistries.
Source: US FDA prescribing information
The most common (≥ 10%) adverse reactions were alopecia, nausea/vomiting, hematuria, leukopenia, anemia, CNS toxicity, infection.
Source: US FDA prescribing information
• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide.
Source: US FDA prescribing information
Store at controlled room temperature 20°C to 25°C (68°F to 77°F). Protect from temperatures above 30°C (86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Ifosfamide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ifosfamide 1 g/20 mL powder for injectionIntravenousGeneric name | — | US FDA | Available on request |
| Ifosfamide 1 g/20 mL injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Ifosfamide 3 g/60 mL injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Ifex 1 g/20 mL powder for injectionIntravenous | Baxter Healthcare | US FDA | Available on request |
| Ifosfamide 1 g powder for injectionIntravenousGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 14 August 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Ifosfamide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 5 presentations of Ifosfamide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ifosfamide, including Ifex.
Yes. The US FDA first approved Ifosfamide on 14 August 1987, according to Drugs@FDA.
At least one listed presentation of Ifosfamide must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Ifosfamide is classified under ATC code L01AA06 (Ifosfamide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.